-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $235

Benzinga·07/09/2026 14:10:49
Listen to the news
Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $205 to $235.